This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
2 Nov 2011

Roche Receives FDA Approval for Acute Hepatitis B Test

With this approval, Roche now offers a full selection of hepatitis tests in its immunoassay portfolio.

Basel-based healthcare company Roche announced Monday that the U.S. FDA granted Premarket Approval (PMA) for its IgM antibody to hepatitis B core antigen (Anti-HBc IgM) assay for use on the cobas e 601 analyzer, the immunoassay module of the cobas? 6000 analyzer series for mid-volume laboratories.

 

The test represents the final component of the acute panel within the hepatitis test menu for the cobas 6000 series.

 

The Anti-HBc IgM assay is used for the in-vitro qualitative determination of IgM antibodies to hepatitis B core antigen (anti-HBc IgM) in human serum or plasma.  The presence of anti-HBc IgM, in conjunction with other laboratory results and clinical information, is indicative of an acute or recent hepatitis B virus (HBV) infection. The assay is

Related News